AMD3100 improves ovariectomy-induced osteoporosis in mice by facilitating mobilization of hematopoietic stem/progenitor cells

Inhibition of an increase of osteoclasts has become the mostimportant treatment for osteoporosis. The CXCR4 antagonist, AMD3100, plays an important role in the mobilization ofosteoclast precursors within bone marrow (BM). However, theactual therapeutic impact of AMD3100 in osteoporosis has notyet be...

Full description

Saved in:
Bibliographic Details
Published in:BMB reports 2014-08, Vol.47 (8), p.439-444
Main Authors: Im, Jin Young, Min, Woo-Kie, Park, Min Hee, Kim, NamOh, Lee, Jong Kil, Jin, Hee Kyung, Choi, Je-Yong, Kim, Shin-Yoon, Bae, Jae-Sung
Format: Article
Language:Korean
Subjects:
AMD3100
Hematopoietic stem/Progenitor cell
Mobilization
Osteoclast
Osteoporosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhibition of an increase of osteoclasts has become the mostimportant treatment for osteoporosis. The CXCR4 antagonist, AMD3100, plays an important role in the mobilization ofosteoclast precursors within bone marrow (BM). However, theactual therapeutic impact of AMD3100 in osteoporosis has notyet been ascertained. Here we demonstrate the therapeuticeffect of AMD3100 in the treatment of ovariectomy-inducedosteoporosis in mice. We found that treatment with AMD3100resulted in direct induction of release of SDF-1 from BM toblood and mobilization of hematopoietic stem/progenitor cells(HSPCs) in an osteoporosis model. AMD3100 prevented bonedensity loss after ovariectomy by mobilization of HSPCs, suggesting a therapeutic strategy to reduce the number ofosteoclasts on bone surfaces. These findings support thehypothesis that treatment with AMD3100 can result in efficientmobilization of HSPCs into blood through direct blockade ofthe SDF-1/CXCR4 interaction in BM and can be considered asa potential new therapeutic intervention for osteoporosis.
ISSN:1976-6696
1976-670X